The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis

The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis

Bibliographic Details
Main Authors:	Xiangwen Liang, Wenchao Xie, Zhihai Lin, Ming Liu
Format:	Article
Language:	English
Published:	KARE Publishing 2021-02-01
Series:	Anatolian Journal of Cardiology
Online Access:	https://anatoljcardiol.com/jvi.aspx?un=AJC-18049&volume=25&issue=2

Similar Items

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis
by: Yapeng Wang, et al.
Published: (2023-01-01)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
by: Mohammed M. Alsultan, et al.
Published: (2023-11-01)

Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
by: Kazuya Naito, et al.
Published: (2020-08-01)

Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
by: Hidehira Fukaya
Published: (2020-08-01)

Safety and efficacy of dabigatran versus warfarin in Asian patients with atrial fibrillation
by: Inche Mat, Liyana Najwa, et al.
Published: (2020)

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
by: O. O. Shakhmatova
Published: (2020-12-01)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
by: Eri Toda Kato, et al.
Published: (2016-05-01)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016-05-01)

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
by: Roisin Bavalia, et al.
Published: (2021-07-01)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
by: Alejandro Bimbo Diaz, et al.
Published: (2023-09-01)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
by: Bimbo Diaz, Alejandro, et al.
Published: (2023)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
by: Christina L. Fanola, et al.
Published: (2018-08-01)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
by: Line Melgaard, et al.
Published: (2021-12-01)

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis
by: Bailin Zhang, et al.
Published: (2023-11-01)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
by: Yi‐Hsin Chan, et al.
Published: (2018-04-01)

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
by: Gregory Y. H. Lip, et al.
Published: (2020-06-01)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
by: Shin-Yi Lin, et al.
Published: (2021-09-01)

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
by: Eue-Keun Choi, et al.
Published: (2021-11-01)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
by: Alexandros Briasoulis, et al.
Published: (2018-04-01)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
by: Pável Olivera, et al.
Published: (2023-06-01)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
by: Hongxia Li, et al.
Published: (2021-09-01)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
by: Emilie Clay, et al.
Published: (2018-01-01)

Unsolved issues of The Efficacy and Safety of Edoxaban
by: Leszek Drabik, et al.
Published: (2021-06-01)

Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban
by: O. L. Barbarash, et al.
Published: (2020-11-01)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
by: Daisuke Fukamachi, et al.
Published: (2022-01-01)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
by: Brandon K. Martinez, et al.
Published: (2018-04-01)

Warfarin and its role in the prevention of thromboembolism in atrial fibrillation (lecture)
by: Y. V. Shubik
Published: (2015-12-01)

Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study).
by: Mavaddat, N, et al.
Published: (2014)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement.
by: Victor Chien-Chia Wu, et al.
Published: (2020-01-01)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS score ⩾ 2
by: Maria M Fernandez, et al.
Published: (2015-11-01)

Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method
by: M. Yu. Kolesnyk, et al.
Published: (2022-09-01)

The use of warfarin in veterans with atrial fibrillation
by: Rosenbeck Karen, et al.
Published: (2004-10-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis
by: Ghulam Murtaza, et al.
Published: (2021-07-01)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
by: Ingrid M. Bistervels, et al.
Published: (2022-07-01)

Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study)
by: Giovanni Frisullo, et al.
Published: (2020-12-01)

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.
by: Soyon Lee, et al.
Published: (2012-01-01)

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers
by: Chenguang Yang, et al.
Published: (2022-06-01)

LEFT ATRIAL APPENDAGE CLOSURE AS AN ALTERNATIVE TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION: A PATIENT¬LEVEL META¬ANALYSIS
Published: (2016-03-01)